Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Namodenoson

    Client Email Product

    Namodenoson

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    0

    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    0

    API REF. PRICE (USD / KG)

    0

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    0

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    25
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Can-Fite: Namodenoson Long-Term CR in Advanced Liver Cancer Patient
    Can-Fite: Namodenoson Long-Term CR in Advanced Liver Cancer Patient

    https://www.businesswire.com/news/home/20240425661063/en

    BUSINESSWIRE
    25 Apr 2024
    Share Share
    Can-Fite: Namodenoson Promising For Liver Cancer, MASH
    Can-Fite: Namodenoson Promising For Liver Cancer, MASH

    https://www.businesswire.com/news/home/20240415044511/en

    BUSINESSWIRE
    15 Apr 2024
    Share Share
    Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed
    Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed

    https://www.businesswire.com/news/home/20240311582155/en

    BUSINESSWIRE
    11 Mar 2024
    Share Share
    Can-Fite:Complete Response in Patient with Liver Cancer Treated with Namodenoson
    Can-Fite:Complete Response in Patient with Liver Cancer Treated with Namodenoson

    https://www.businesswire.com/news/home/20231121112108/en

    BUSINESSWIRE
    21 Nov 2023
    Share Share
    Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives from (ASCO)
    Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives from (ASCO)

    https://www.businesswire.com/news/home/20230530005167/en

    BUSINESSWIRE
    30 May 2023
    Share Share
    Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Companies
    Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Companies

    https://www.businesswire.com/news/home/20230316005101/en

    BUSINESSWIRE
    16 Mar 2023
    Share Share
    Novel Approach to Treating Liver Cancer with Namodenoson Published in Journal
    Novel Approach to Treating Liver Cancer with Namodenoson Published in Journal

    https://www.businesswire.com/news/home/20230214005420/en

    BUSINESSWIRE
    14 Feb 2023
    Share Share
    Can-Fite to Present its PhIIb NASH Drug Candidate Namodenoson at Conference
    Can-Fite to Present its PhIIb NASH Drug Candidate Namodenoson at Conference

    https://www.businesswire.com/news/home/20221013005106/en

    BUSINESSWIRE
    13 Oct 2022
    Share Share
    Can-Fite’s Drug Namodenoson Approved for Treatment of Liver Cancer Patients
    Can-Fite’s Drug Namodenoson Approved for Treatment of Liver Cancer Patients

    https://www.businesswire.com/news/home/20220823005373/en

    BUSINESSWIRE
    23 Aug 2022
    Share Share
    Namodenoson’s Liver Fibrosis Treatment Receives Notice of Allowance from USPTO
    Namodenoson’s Liver Fibrosis Treatment Receives Notice of Allowance from USPTO

    https://www.businesswire.com/news/home/20220314005244/en

    BUSINESSWIRE
    14 Mar 2022
    Share Share
    Can Fite Begins Enrollment in Phase IIb NASH Clinical Trial with Namodenoson
    Can Fite Begins Enrollment in Phase IIb NASH Clinical Trial with Namodenoson

    https://www.businesswire.com/news/home/20220131005278/en

    BUSINESSWIRE
    31 Jan 2022
    Share Share
    Liver Cancer Patient Treated with Namodenoson Clears All Cancer Lesions
    Liver Cancer Patient Treated with Namodenoson Clears All Cancer Lesions

    https://www.businesswire.com/news/home/20211220005270/en

    BUSINESSWIRE
    20 Dec 2021
    Share Share
    Can-Fite CEO to Present Namodenoson’s Clinical Trial Data
    Can-Fite CEO to Present Namodenoson’s Clinical Trial Data

    https://www.businesswire.com/news/home/20211026005086/en

    BUSINESSWIRE
    26 Oct 2021
    Share Share
    Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting
    Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting

    https://www.businesswire.com/news/home/20201124005430/en

    BUSINESSWIRE
    24 Nov 2020
    Share Share
    Can-Fite Receives Notice of Allowance for Namodenoson Patent NASH & NAFLD
    Can-Fite Receives Notice of Allowance for Namodenoson Patent NASH & NAFLD

    https://www.businesswire.com/news/home/20200521005252/en

    BUSINESSWIRE
    21 May 2020
    Share Share
    Can-Fite is Filing Drug Safety Update-Ph II & Ph III Namodenoson & Piclidenoson
    Can-Fite is Filing Drug Safety Update-Ph II & Ph III Namodenoson & Piclidenoson

    https://www.businesswire.com/news/home/20200303005502/en

    BUSINESSWIRE
    03 Mar 2020
    Share Share
    Can Fite Files Patent for Namodenoson to Overcome Drug Resistance
    Can Fite Files Patent for Namodenoson to Overcome Drug Resistance

    https://www.businesswire.com/news/home/20200224005267/en

    BUSINESSWIRE
    24 Feb 2020
    Share Share
    Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea
    Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea

    https://www.businesswire.com/news/home/20200218005545/en

    BUSINESSWIRE
    18 Feb 2020
    Share Share
    Data from the Phase II Liver Cancer Study with Namodenoson will be presented
    Data from the Phase II Liver Cancer Study with Namodenoson will be presented

    https://www.businesswire.com/news/home/20200107005606/en

    BUSINESS WIRE
    08 Jan 2020
    Share Share
    Data from the Phase II Liver Cancer Study with Namodenoson will be presented
    Data from the Phase II Liver Cancer Study with Namodenoson will be presented

    https://www.businesswire.com/news/home/20200107005606/en

    BUSINESS WIRE
    07 Jan 2020
    Share Share
    Data from the Phase II Liver Cancer Study with Namodenoson will be presented
    Data from the Phase II Liver Cancer Study with Namodenoson will be presented

    https://www.businesswire.com/news/home/20200107005606/en

    BUSINESS WIRE
    07 Jan 2020
    Share Share
    USFDA Agreed with Can-Fite’s Proposed Pivotal PhIII Trial to Support a NDA Sub
    USFDA Agreed with Can-Fite’s Proposed Pivotal PhIII Trial to Support a NDA Sub

    https://www.businesswire.com/news/home/20191031005459/en

    BUSINESSWIRE
    31 Oct 2019
    Share Share
    Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™
    Can-Fite Completes Patient Enrollment in Phase II NASH Study of Namodenoson™

    https://www.businesswire.com/news/home/20191015005467/en/Can-Fite-Completes-Patient-Enrollment-Phase-II-NASH/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSNEWSWIRE
    15 Oct 2019
    Share Share
    Drugs with MOA Utilized by Namodenoson Recommended to Combat Liver Cancer
    Drugs with MOA Utilized by Namodenoson Recommended to Combat Liver Cancer

    https://www.businesswire.com/news/home/20180702005387/en/Drugs-Mechanism-Action-Utilized-Namodenoson-Recommended-Leading

    BUSINESSWIRE
    02 Jul 2018
    Share Share
    Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson
    Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson

    https://www.businesswire.com/news/home/20180611005354/en

    BUSINESSWIRE
    11 Jun 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search